SCHEMBL4327484

SCHEMBL4327484

O=C(O)CCC(NC(=O)NC(CCCCNC(=O)Nc1ccccc1)C(=O)O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 18/20 1.00
▸ GAA P10253 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11977601 1.00 FOLH1 (1.00) FOLH1GAA
SCHEMBL22365104 1.00 FOLH1 (1.00) FOLH1GAA
SCHEMBL4327488 0.95 FOLH1 (0.91) FOLH1GAA
SCHEMBL19756834 0.93 FOLH1 (0.86) FOLH1GAA
SCHEMBL11977630 0.91 FOLH1 (0.83) FOLH1GAA
SCHEMBL20335021 0.91 FOLH1 (0.83) FOLH1
SCHEMBL20335023 0.91 FOLH1 (0.83) FOLH1
SCHEMBL11977629 0.89 FOLH1 (0.80) FOLH1
SCHEMBL11977603 0.89 FOLH1 (1.00) FOLH1
Mip-1095 I-123 SCHEMBL4326617 0.89 FOLH1 (1.00) FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) 2012-08-16 — — US claimed
EP-2097111-A2 HETERODIMERS OF GLUTAMIC ACID Molecular Insight Pharmaceuticals, Inc. (US) 2009-09-09 — — EP claimed
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-08-14 — — US claimed
WO-2008058192-A2 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2008-05-15 — — WO claimed
US-12534429-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2026-01-27 — — US disclosed
US-20230095637-A1 Heterodimers of Glutamic Acid CITIZENS BANK, N.A. 2023-03-30 — — US disclosed
EP-4023624-A1 HETERODIMERS OF GLUTAMIC ACID Molecular Insight Pharmaceuticals, Inc. (US) 2022-07-06 — — EP disclosed
EP-3699162-B1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARM INC (US) 2022-06-29 — — EP disclosed
US-20220194904-A1 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS CORNELL UNIVERSITY (US) 2022-06-23 — — US disclosed
US-20210246103-A1 HETERODIMERS OF GLUTAMIC ACID CITIZENS BANK, N.A. 2021-08-12 — — US disclosed
US-20210070695-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2021-03-11 — — US disclosed
US-20210070696-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2021-03-11 — — US disclosed
US-8487129-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2013-07-16 — — US disclosed
US-20120269726-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2012-10-25 — — US disclosed
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) 2012-08-16 — — US disclosed
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) 2012-08-16 — — US disclosed
EP-2097111-A2 HETERODIMERS OF GLUTAMIC ACID Molecular Insight Pharmaceuticals, Inc. (US) 2009-09-09 — — EP disclosed
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-08-14 — — US disclosed
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-08-14 — — US disclosed
WO-2008058192-A2 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2008-05-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070695-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885GAA 507/4885
US-12534429-B2 Heterodimers of glutamic acid FOLH1, GLUL, SLC25A13 FOLH1 1/4885GAA 713/4885
US-20120269726-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS FOLH1 5/4885GAA 504/4885
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885GAA 507/4885
US-20210070696-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885GAA 463/4885
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885GAA 507/4885
US-20230095637-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS FOLH1 5/4885GAA 513/4885
US-20210246103-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885GAA 507/4885
US-20220194904-A1 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS PSMA3, FOLH1, PSMA1 FOLH1 2/4885GAA 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback